Acute and Subchronic Oral Toxicities of Benzo[a]pyrene in F-344 Rats

Abstract

We have studied the acute and subchronic oral toxicities of benzo[a]pyrene (BaP) in male and female F-344 rats. Single acute BaP doses of 0, 100, 600, and 1000 mg /kg dissolved in peanut oil were administered by oral gavage. Subchronic doses of 0, 5, 50, and 100 mg/kg/day were administered for 90 days in the animal diet. The major toxicological endpoints examined included animal body weight, selected tissue weights, and histopathological examinations (liver, kidney, stomach, prostate, testes, and ovaries). In addition, we examined blood elements: red blood cells (RBC), white blood cells (WBC), hemoglobin (Hgb), hematocrit (Hct), mean cell volume (MCV), mean cell hematocrit (MCH), and mean cell hemoglobin concentration (MCHC), blood chemistry (ALT, AST, and BUN), and urine chemistry (glucose, bilirubin, specific gravity, pH, protein, urobilinogen, nitrite, occult blood, and leucocytes). In the acute study, WBC were significantly decreased and mean cell-hemoglobin concentration was significantly increased, both in males only. The liver:body weight ratio was significantly increased in males and females (up to 30%). None of the blood chemistry or urine parameters were significantly affected. In the subchronic study, mean body weight was significantly decreased in males only (13%), and the liver:body weight ratio in males was significantly increased. Several of the blood elements were significantly decreased in males and females after 90 days; RBCs (up to 10%), Hct (up to 12%), and Hgb (up to 12%). For blood chemistry parameters (AST, ALT, BUN), only BUN in males was significantly increased in the high dose group (100 mg/kg) at the 90 day time point. The histopathological examination of selected tissues showed significant abnormalities (tubular casts) only in the male kidney, at the 2 highest doses, after 90 days. These studies indicate that the acute and subchronic toxicities of BaP are relatively low, BaP affects specific blood elements and organs, and BaP has a greater effect on males than females. The induction of non-carcinogenic kidney abnormalities in males only may be indicative of renal dysfunction and further substantiates an apparent sex difference in tolerance to BAP:

Profiling the Hepatic Effects of Flutamide in Rats: A Microarray Comparison With Classical Aryl Hydrocarbon Receptor Ligands and Atypical Cyp1a Inducers

“…2). Potent AhR ligands are known to increase liver weight (Knuckles et al, 2001;Waring et al, 2001Waring et al, , 2002, and all three classical AhR ligands showed a modest increase in % LW/BW, although because of the singlicate design, significance was not measured. CLO (250 mg/kg/day) resulted in the largest increase of % LW/BW at 5.2, a 62% increase from vehicle control animals.…”

“…CLO (31.3 mg/kg/day, a mid-range dose) was an apparent outlier with the highest increase in ALT at 66 U/l, which was ϳ4-fold greater than the upper limit of normal in control-treated animals (17 U/l). 3MC and BAP are known to perturb clinical chemistry and/or liver histopathology in rats at time points longer than the 3-day dose schedule used here (Knuckles et al, 2001;Kondraganti et al, 2005).…”

Integrating Field Analyses with Laboratory Exposures to Assess Ecosystems Health

“…In addition, limited data are available concerning the potential renal toxicity of PAHs (see ATSDR, 1995). Some recent studies indicate that benzo [a]pyrene may exhibit limited hepato-and nephrotoxic effects at high doses (De Jong et al, 1999;Knuckles et al, 2001;Kroese et al, 2001). …”

Disruption of glomerular cell-cell and cell-matrix interactions in hydrocarbon nephropathy

“…Other sites of the nephron including the proximal tubule are not affected (23), suggesting that region-selective patterns of gene and protein expression influence pathogenetic outcomes. Subchronic oral dosing of male rats with BaP induces renal cast formation (29). Repeated challenge of glomerular cells in culture with BaP and related aromatic hydrocarbons induce phenotypic changes (2) and altered mitogenic signaling (44).…”